Albumin adjuvant therapy for acute ischemic stroke with large vessel occlusion (AMASS-LVO): rationale, design, and protocol for a phase 1, open-label, clinical trial.

MLA

Pan, Sihu, et al. “Albumin Adjuvant Therapy for Acute Ischemic Stroke with Large Vessel Occlusion (AMASS-LVO): Rationale, Design, and Protocol for a Phase 1, Open-Label, Clinical Trial.” Frontiers in Neurology, Nov. 2024, pp. 1–7. EBSCOhost, https://doi.org/10.3389/fneur.2024.1455388.

APA

Pan, S., Du, K., Liu, S., Wang, S., Luo, L., Xu, Y., Cao, C., Chen, J., Ji, X., & Wei, M. (2024). Albumin adjuvant therapy for acute ischemic stroke with large vessel occlusion (AMASS-LVO): rationale, design, and protocol for a phase 1, open-label, clinical trial. Frontiers in Neurology, 1–7. https://doi.org/10.3389/fneur.2024.1455388

Chicago

Pan, Sihu, Kangjie Du, Shuling Liu, Sifei Wang, Leilei Luo, Yongbo Xu, Chen Cao, Jian Chen, Xunming Ji, and Ming Wei. 2024. “Albumin Adjuvant Therapy for Acute Ischemic Stroke with Large Vessel Occlusion (AMASS-LVO): Rationale, Design, and Protocol for a Phase 1, Open-Label, Clinical Trial.” Frontiers in Neurology, November, 1–7. doi:10.3389/fneur.2024.1455388.